EHA 2022 | Identifying new subtype-defining lesions in pediatric T-ALL
David Teachey, MD, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, comments on the results of a study investigating the genomic basis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) using whole-genome sequencing (WGS), whole-exome sequencing (WES) and RNA-sequencing (RNA-seq) to define T-ALL subtypes. Overall, the study identified new subtype-defining lesions in this disease, with over half of them in non-coding regions of the genome. Dr Teachy explains that ongoing research is investigating the association between this genetic data and outcomes, hoping that the results will enable us to identify patients that are more likely to relapse and select appropriate treatment strategies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
